|
| Register for our Free Newsletters |
|
 |
|
|
|
|
|
|
|
|
| Other Carouselweb publications |
|
|
|
|
|
|
|
|
|
|
| |
| |
|
|
|
|
|
|
|
|
LGC and AKOS combine to offer expanded drug development services
|
|
LGC
: 22 March, 2004 (Company News) |
|
|
LGC, Europe's leading independent provider of chemical, biochemical and forensic analysis, has formed a strategic alliance with AKOS, the UK-based specialist drug development and regulatory affairs consultancy company, that will enable both parties to expand the range of services they offer to drug discovery companies. |
|
AKOS specialises in leading clients from drug discovery through the development process, and has a strong track record of enabling organisations to achieve their strategic aims, including onward sale or licensing, through to marketing authorisation. LGC offers a wide range of analytical services and instrumentation that are applied across the drug development cycle from early phase discovery through to clinical trial. Through this alliance clients will benefit from the best in advice and services that will enhance the development and valuation of new products.
Dr Derek Craston, Head of LGC's Pharmaceutical Services, said: 'We are very excited about this collaboration and see AKOS as a natural and synergistic partner in providing high value services to the pharmaceutical and biotechnology sectors. LGC has strong links with Government and regulators, and is committed to supplying high quality analytical services in support of drug discovery. We are impressed with AKOS and the nearly 20 years of experience that this company has in advising on all types of regulatory compliance issues and providing other services relating to clinical trials and marketing authorisation applications, in Europe, North America and other parts of the world. Together, LGC and AKOS will be able provide top class support to companies from the earliest phases of lead identification through to market launch.'
Paul Evans, Chairman and Managing Director of AKOS, commented: 'AKOS is both a service company and a consultancy: we tailor our response to the clinical, financial or administration needs of the client, working with them from the preclinical phase of drug discovery through early clinical development to 'proof of concept'. LGC has a world class reputation for quality and offers a broad range of analytical services, from synthesis and biomeasurement to formulation development. We look forward to working with LGC and we believe that together, AKOS and LGC can develop a win-win relationship.' |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
